Testing specialties
Gastroenterology
Gastroenterology
Our integration with a world-renowned medical center equips us with patient experience that supports development of disease-specific, algorithmic-based testing approaches that provide faster answers for each patient. Whether screening patients or monitoring therapeutic management, our evaluations cover the full-spectrum of gastroenterology testing.
Genetics
Genetics
Mayo Clinic Laboratories has been providing meaningful results to individuals seeking genetic answers. Rare genetic disorders can be among the most difficult conditions to diagnose. To provide meaningful answers, our genetic testing is developed and supported by an integrated team of clinical, genetic, and laboratory experts and uses precision technologies to reveal variations related to diagnosis and treatment. Built around a tradition of placing patients’ needs first, our testing generates personalized insights to elevate understanding of a patient’s condition.
Hematology
Hematology
Our comprehensive test menu has been created to aid in diagnosis and treatment selection across the full spectrum of hematologic disorders. We have developed and validated practice-based, data-driven algorithms that improve patient care, increase efficiency, and reduce costs. Our hematology experts continuously drive innovation in laboratory testing, developing new approaches and using new technology to address patient needs they see every day in clinical practice.
Microbiology & Infectious Diseases
Microbiology & Infectious Diseases
Our internationally renowned clinical microbiology laboratories offer a broad selection of tests designed for rapid identification and in-depth characterization of the causative agents of infectious diseases. We have developed and implemented culture techniques, immunoassays, antimicrobial susceptibility testing, and molecular methods for rapid detection, identification, and characterization, as well as provision of treatment guidance for microbial pathogens.
Neurology
Neurology
Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.
Oncology
Oncology
Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.
Pathology
Pathology
Mayo Clinic has the most robust laboratory and pathology practice for cancer care in the world, offering testing that spans diagnostic, theranostic, and prognostic approaches. Integrated teams of Mayo Clinic pathologists provide expertise for every type and stage of cancer. Our consultative practice strives to provide the highest quality of diagnostic pathology, utilizing only ancillary testing that supports diagnosis in a cost-effective, expedient manner.
Renal
Renal
With over 150 years of advanced medical knowledge, our multidisciplinary approach and award-winning team of nephrology experts, pathologists, and laboratory scientists provides the highest standards for renal laboratory care. We believe laboratory medicine offers more than a test result — it is about collaboration to reach actionable answers for patients. Currently, Mayo Clinic physicians are actively enrolling in clinical trials to make patient needs central to the care journey.
Pediatrics
Pediatrics
Mayo Clinic Laboratories understands your need to deliver timely and exceptional care to your pediatric patients. That’s why we deliver the most patient-focused reference lab experience possible. Unlike other reference labs, we offer advanced and accurate testing methods supported by access to world-renowned Mayo Clinic specialists and over 150 years of experience informing diagnoses and treatment plans to improve the health of children. Because we know it’s not only about giving children the right care, it’s about giving them the best care.
Therapeutics
Therapeutics
Therapeutics testing covers a wide range of areas from controlled substance monitoring to pharmacogenomics (PGx). Our testing delivers clarity on drug use to advance understanding and improve patient outcomes. We provide access to Mayo Clinic experts and a test menu developed through evidence-driven clinical innovation to help clinicians guide patient care.
Other Testing
Other Testing
Patients everywhere deserve access to world-class diagnostic care. Our test catalog covers the full range of clinical specialties, with more than 4,400 tests available to support care for your patients. And with Mayo Clinic physicians and scientists driving research and test development, our assays are backed by some of the world’s leading subspecialists, who are available to discuss any test order, result, or diagnostic next steps for your patients.
News and updates
Building Momentum for Outreach Implementation Success
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Ellen Dijkman Dulkes and Brianne Newton. They discuss common reasons that outreach programs fail to launch and strategies for building momentum to implement a program.
Precision in the pancreas: A new genetic test transforms hereditary pancreatitis diagnosis and care
Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.
Cytology Specimen Utilization: A Proven Approach to Genetic Sequencing
PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.
Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing
Mayo Clinic Laboratories and KYAN Technologies announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States.
Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services
Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.
Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
Fergus Couch, Ph.D., co-authors new guidelines for interpreting ATM cancer gene variants
Fergus Couch, Ph.D., chair of Mayo Clinic’s Division of Experimental Pathology and Laboratory Medicine, led a team that recently published new National Institutes of Health and U.S. Food and Drug Administration-approved guidelines for the interpretation of variants in the ataxia telangiectasia mutated (ATM) cancer gene. Inherited mutations in ATM have been shown to increase the risk of breast, pancreatic, and prostate cancers. Now published by the American Journal of Human Genetics and available for widespread use, Dr. Couch says the guidelines can help clinicians around the world apply the same consistent method of classification to ATM variants.
Dr. Dong Chen and Dr. Sounak Gupta join Becker’s Healthcare Podcast to discuss molecular testing in cancer care
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC
Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many kinds of cancer.
Optimizing Cancer Care: ASCO Guidelines for Germline Genetic Testing
PACE/State of FL - The latest ASCO guidelines for selection of germline genetic testing panels for cancer patients.
Advanced Diagnostics Laboratory helps improve the way oncologists treat patients through development of the Mayo Complete Solid Tumor Panel
Founded in 2017, Mayo Clinic's Advanced Diagnostics Laboratory is a visionary space. In 2021, the lab developed the Mayo Complete Solid Tumor Panel, a clinically validated assay that analyzes 515 genes using next-generation sequencing. This multiple test panel, the first of its kind at Mayo, aids in selecting targeted therapies, diagnosing tumor types, and predicting prognosis, significantly improving patient care.
A shared journey through breast cancer: Samantha Duke and Jane Hanson
When Samantha Duke discovered she had breast cancer, she didn’t have to look far for support. Her mother Jane walked a similar path 16 years earlier. Inspired both by her mom and the strong network of healthcare physicians and professionals on her team, Samantha remained positive throughout her treatment and is committed to advancing research on breast cancer.
Mayo Clinic Laboratories is the global leader in diagnostics, dedicated to collaborative discoveries and patient breakthroughs. Together with Mayo Clinic, we relentlessly innovate on behalf of patients, building the diagnostics ecosystem of the future to help physicians save and improve more lives.
3:47
Watch our “Life of a Specimen” video series, offering a close-up look at the path taken by patient specimens and the journey of a patient whose life was profoundly impacted by Mayo Clinic Laboratories.
Providing more precise and complete diagnostic data, clinical analysis, and consultation services beyond just a test result.
50+
years of helping hospitals maximize the value of their labs
4.4K
tests and pathology services to answer the most difficult clinical questions
5.7K
Mayo Clinic physicians and scientists available for consultation 24/7
26M
tests performed annually that deliver fast, accurate answers